

**SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

Application Number	10/551,209
Filing Date	September 28, 2005
First Named Inventor	Denise Marie BAKER
Art Unit	1644
Examiner Name	M. DiBrino
Attorney Docket Number	2473.0260001/EKS/PAC

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

1071332v1

Examiner Signature	/Marianne Dibrino/	Date Considered	04/06/2010
-----------------------	--------------------	--------------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Indicate type of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

English language translation is required. See 37 CFR 1.97 and 1.98. The information is gathered by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This benefit is estimated to take 2 hours to complete, including preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Advancements on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (M.D.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	1	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	NPL159	Alexander, J., <i>et al.</i> , "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <i>Immunity</i> 1:751-761, Cell Press, Massachusetts (1994)			
	NPL160	Alonso, M.J., <i>et al.</i> , "Biodegradable Microspheres as Controlled-release Tetanus Toxoid Delivery System," <i>Vaccine</i> 12:299-306, Elsevier Ltd., London (1994)			
	NPL161	Alter, H.J., "Chronic Consequences of Non-A, Non-B Hepatitis," in <i>Current Perspectives in Hepatology</i> , eds., Seeff, L.B., and Lewis, J.H., pp. 83-97, Plenum Publishing Corporation, New York (1989)			
	NPL162	Alter, M.J., <i>et al.</i> , "The Natural History of Community-Acquired Hepatitis C in the United States," <i>The New England Journal of Medicine</i> 327:1899-1905, Massachusetts Medical Society, Boston (1992)			
	NPL163	Altman, J.D., <i>et al.</i> , "Formation of Functional Peptide Complexes of Class II Major Histocompatibility Complex Proteins from Subunits Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 90:10330-10334, National Academy of Sciences (1993)			
	NPL164	Altman, J.D., <i>et al.</i> , "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> 274:94-96, The American Association for the Advancement of Science, Washington DC, USA (1993)			
	NPL165	Altuvia, Y., <i>et al.</i> , "Ranking Potential Binding Peptides to MHC Molecules by a Computational Threading Approach," <i>Journal of Molecular Biology</i> 249:244-250, Academic Press, London (1995)			
	NPL166	Altuvia, Y., <i>et al.</i> , "A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets," <i>Human Immunology</i> 58:1-11, Elsevier Science Inc., New York, USA (1997)			
	NPL167	An, L and Whitton, J.L., "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T <sub>H</sub> Epitopes from Several Microbes, Includes Appropriate Responses In Vivo and Confers Protection Against More than One Pathogen," <i>Journal of Virology</i> 71:2292-2302, American Society for Microbiology, Washington DC, USA (1997)			
	NPL168	Barber, L.D., <i>et al.</i> , "Overlap in the Repertoires of Peptides Bound In Vivo by a Group of Related Class I HLA-B Allotypes," <i>Current Biology</i> 5:179-190, Current Biology Ltd., London (1995)			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	2	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T <sup>2</sup>
	NPL169	Borrow, P., <i>et al.</i> , "Antiviral Pressure Exerted by HIV-1-Specific Cytotoxic T Lymphocytes (CTLs) During Primary Infection Demonstrated by Rapid Selection of CTL Escape Virus," <i>Nature Medicine</i> 3:205-211, Nature Publishing Co., New York (1997)		
	NPL170	Brusic, V., <i>et al.</i> , "Prediction of MHC Class II-binding Peptides Using an Evolutionary Algorithm and Artificial Neural Network," <i>Bioinformatics</i> 14:121-130, Oxford University Press, Oxford, UK (1998)		
	NPL171	Busch, R., <i>et al.</i> , "Degenerate Binding of Immunogenic Peptides to HLA-DR Proteins on B Cell Surfaces," <i>International Immunology</i> 2:443-451, Oxford University Press, Oxford, UK (1990)		
	NPL172	Buus, S., "Description and Prediction of Peptide-MHC Binding: the 'Human MHC Project'," <i>Current Opinion in Immunology</i> 11:209-213, Current Biology Publications, London (1999)		
	NPL173	Ceppellini, R., <i>et al.</i> , "Binding of Labelled Influenza Matrix Peptide to HLA DR in Living B Lymphoid Cells," <i>Nature</i> 339:392-394, Macmillan Magazines Ltd., London (1989)		
	NPL174	Cerundolo, V., <i>et al.</i> , "The Binding Affinity and Dissociation Rates of Peptides for Class I Major Histocompatibility Complex Molecules," <i>European Journal of Immunology</i> 21:2069-2075, VCH Verlagsgesellschaft mbH, Germany (1991)		
	NPL175	Chakrabarti, S., <i>et al.</i> , "Expression of the HTLV-III Envelope Gene by a Recombinant Vaccinia Virus," <i>Nature</i> 320:535-537, Macmillan Journals Ltd., London (1986)		
	NPL176	Chanda, P.K., <i>et al.</i> , "High Level Expression of the Envelope Glycoproteins of the Human Immunodeficiency Virus Type I in Presence of Rev Gene Using Helper-Independent Adenovirus Type 7 Recombinants," <i>Virology</i> 175:535-547, Academic Press Inc., USA (1990)		
	NPL177	Chisari, F.V., and Ferrari, C., "Hepatitis B Virus Immunopathogenesis," <i>Annual Review of Immunology</i> 13:29-60, Annual Reviews Inc., Palo Alto, California, USA (1995)		
	NPL178	Choo, Q., <i>et al.</i> , "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome," <i>Science</i> 244:359-362, American Association for the Advancement of Science, Washington DC, USA (1989)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	3	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	NPL179	Christnick, E.R., et al., "Peptide Binding to Class I MHC on Living Cells and Quantitation of Complexes Required for CTL Lysis," <i>Nature</i> 352:67-70, Macmillan Magazines Ltd., London (1991)		
	NPL180	Cooney, E.L., et al., "Enhanced Immunity to Human Immunodeficiency Virus (HIV) Envelope Elicited by a Combined Vaccine Regimen Consisting of Priming with a Vaccinia Recombinant Expressing HIV Envelope and Boosting with gp160 Protein," <i>Proc. Natl. Acad. Sci. USA</i> 90:1882-1886, National Academy of Sciences (1993)		
	NPL181	Cornette, J.L., et al., "Hydrophobicity Scales and Computational Techniques for Detecting Amphipathic Structures in Proteins," <i>Journal of Molecular Biology</i> 195:659-685, Academic Press Inc., London (1987)		
	NPL182	Dartmann, K., et al., "The Nucleotide and Genome Organization of Human Papilloma Virus Type II," <i>Virology</i> 151:124-130, Academic Press Inc., Florida, USA (1986)		
	NPL183	Davis, G.L., et al., "Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa," <i>The New England Journal of Medicine</i> 321:1501-1506, Massachusetts Medical Society, Boston, USA (1989)		
	NPL184	Deamer, D. and Bangham, A.D., "Large Volume Liposomes by an Ether Vaporization Method," <i>Biochimica et Biophysica Acta</i> 443:629-634, Elsevier Scientific Publishing Company, Amsterdam (1976)		
	NPL185	Dienstag, J.L., "Non-A, Non-B Hepatitis. I. Recognition, Epidemiology, and Clinical Features," <i>Gastroenterology</i> 85:439-462, American Gastroenterological Association, New York, USA (1983)		
	NPL186	Doolan, D.L., et al., "Cytotoxic T Lymphocyte (CTL) Low-Responsiveness to the <i>Plasmodium falciparum</i> Circumsporozoite Protein in Naturally-Exposed Endemic Populations: Analysis of Human CTL Response to Most Known Variants," <i>International Immunology</i> 5:37-46, Oxford University Press, London (1993)		
	NPL187	del Guercio, M., et al., "Binding of a Peptide Antigen to Multiple HLA Alleles Allows Definition of an A2-Like Supertype," <i>The Journal of Immunology</i> 154:685-693, The American Association of Immunologists, Maryland, USA (1995)		
	NPL188	DiBrino, M., et al., "Endogenous Peptide with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8," <i>The Journal of Immunology</i> 152:620-631, The American Association of Immunologists, Maryland, USA (1994)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	4	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL189	Devereux, J., et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Research</i> 12:387-395, IRL Press Limited, Oxford, England (1984)	
	NPL190	Debs, R.J., et al., "Regulation of Gene Expression <i>In Vivo</i> by Liposome-Mediated Delivery of a Purified Transcription Factor," <i>The Journal of Biological Chemistry</i> 265:10189-10192, The American Society for Biochemistry and Molecular Biology, Inc., Baltimore, USA (1990)	
	NPL191	Dunbar, P.R., et al., "Direct Isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes from Peripheral Blood," <i>Current Biology</i> 8:413-416, Current Biology Ltd., London (1998)	
	NPL192	Egan, J.E., et al., "Efficacy of Murine Malaria Sporozoite Vaccines: Implications for Human Vaccine Development," <i>Science</i> 236:453-456, The American Association for the Advancement of Science, Washington DC, USA (1987)	
	NPL193	Eldridge, J.H., et al., "New Advances in Vaccine Delivery Systems," <i>Seminars in Hematology</i> 30:16-25, W.B. Saunders Company, Philadelphia, USA (1993)	
	NPL194	Eldridge, J.H., et al., "Biodegradable Microspheres as a Vaccine Delivery System," <i>Molecular Immunology</i> 28:287-294, Pergamon Press plc., Oxford, UK (1991)	
	NPL195	Fauchere, J. and Pliska, V., "Hydrophobic Parameters $\Pi$ of Amino-Acid Side Chains from the Partitioning of N-Acetyl-Amino-Acid Amides," <i>European Journal of Medicinal Chemistry</i> 18:369-375, S.E.C.T., Paris (1983)	
	NPL196	Felgner, P.L., et al., "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure," <i>Proc. Natl. Acad. Sci. USA</i> 84:7413-7417, National Academy of Sciences (1987)	
	NPL197	Robinson, W.S., "Hepadnaviridae and Their Replication," in <i>Virology, Volume 2, Chapter 26</i> , eds., Fields, B.N., et al., pp. 2137-2169, Raven Press Ltd., New York, USA (1990)	
	NPL198	Fraley, R.T., et al., "Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Potential for Gene Transfer," <i>Proc. Natl. Acad. Sci. USA</i> 76:3348-3352, National Academy of Sciences (1979)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to inform or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/551,209
		Filing Date	September 28, 2005
		First Named Inventor	Denise Marie BAKER
		Art Unit	1644
		Examiner Name	M. DiBrino
		Attorney Docket Number	2473.0260001/EKS/PAC
Sheet	5	of	15

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL199	Fraley, R., et al., "Introduction of Liposome-Encapsulated SV40 DNA into Cells," <i>The Journal of Biological Chemistry</i> 255:10431-10435, The American Society of Biological Chemists, Inc., Baltimore, USA (1980)	
	NPL200	Franco, A., et al., "Pathogenetic Effector Function of CD4-Positive T Helper 1 Cells in Hepatitis B Virus Transgenic Mice," <i>The Journal of Immunology</i> 159:2001-2008, The American Association of Immunologists, Maryland, USA (1997)	
	NPL201	Franke, E.D., et al., "Pan DR Binding Sequence Provides T-cell Help for Induction of Protective Antibodies Against <i>Plasmodium Yoelii</i> Sporozoites," <i>Vaccine</i> 17:1201-1205, Elsevier Science Ltd., Oxford, UK (1999)	
	NPL202	Gilles, P.N., et al., "Tumor Necrosis Factor Alpha Negatively Regulates Hepatitis B Virus Gene Expression in Transgenic Mice," <i>Journal of Virology</i> 66:3955-3960, American Society for Microbiology, Washington DC, USA (1992)	
	NPL203	Graham, B.S., et al., "Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with rgp160 in Vaccinia-Naive Adults," <i>The Journal of Infectious Disease</i> 167:533-537, The University of Chicago Press, Chicago, USA (1993)	
	NPL204	Guidotti, L.G., et al., "Interleukin-2 and Alpha/Beta Interferon Down-Regulate Hepatitis B Virus Gene Expression in Vivo by Tumor Necrosis Factor-Dependent and Independent Pathways," <i>Journal of Virology</i> 68:1265-1270, American Society for Microbiology, Washington DC, USA (1994)	
	NPL205	Guidotti, L.G., et al., "High-Level Hepatitis B Virus Replication in Transgenic Mice," <i>Journal of Virology</i> 69:6158-6169, American Society for Microbiology, Washington DC, USA (1995)	
	NPL206	Guidotti, L.G., et al., "Cytotoxic T Lymphocytes Inhibit Hepatitis B Virus Gene Expression by a Noncytolytic Mechanism in Transgenic Mice," <i>Proc. Natl. Acad. Sci. USA</i> 91:3764-3768, National Academy of (1994)	
	NPL207	Gulukota, K., et al., "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," <i>Journal of Molecular Biology</i> 267:1258-1267, Academic Press, London (1997)	
	NPL208	Haas, G., et al., "Dynamics of Viral Variants in HIV-1 Nef and Specific Cytotoxic T Lymphocytes In Vivo," <i>The Journal of Immunology</i> 157:4212-4221, The American Association of Immunologists, Maryland, USA (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/551,209
		Filing Date	September 28, 2005
		First Named Inventor	Denise Marie BAKER
		Art Unit	1644
		Examiner Name	M. DiBrino
Sheet	6	of	15
		Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL209	Hammer, J., et al., "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," <i>The Journal of Experimental Medicine</i> 180:2353-2358, The Rockefeller University Press, New York, USA (1994)	
	NPL210	Handsfield, H.H., "Clinical Presentation and Natural Course of Anogenital Warts," <i>The American Journal of Medicine</i> 102:16-20, Excerpta Medica Inc., New York, USA (1997)	
	NPL211	Hanke, T., et al., "DNA Multi-CTL Epitope Vaccine for HIV and <i>Plasmodium Falciparum</i> : Immunogenicity in Mice," <i>Vaccine</i> 16:426-435, Elsevier Science Ltd., Oxford, UK (1998)	
	NPL212	Hill, A.V.S., et al., "Molecular Analysis of the Association of HLA-B53 and Resistance to Severe Malaria," <i>Nature</i> 360:434-439, Macmillan Magazine Ltd., London (1992)	
	NPL213	Hill, A.V.S., et al., "Common West African HLA Antigens are Associated with Protection from Severe Malaria," <i>Nature</i> 352:595-600, Macmillan Magazine Ltd., London (1991)	
	NPL214	Hill, C.M., et al., "Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401," <i>The Journal of Immunology</i> 152:2890-2898, The American Association of Immunologists, Maryland, USA (1994)	
	NPL215	Hoffman, S.L., et al., "Sporozoite Vaccine Induces Genetically Restricted T Cell Elimination of Malaria from Hepatocytes," <i>Science</i> 244:1078-1081, American Association for the Advancement of Science, Washington DC, USA (1989)	
	NPL216	Hofmann, K.J., et al., "Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-like Particles in <i>Saccharomyces Cerevisiae</i> ," <i>Virology</i> 209:506-518, Academic Press Inc., Orlando, USA (1995)	
	NPL217	Hoofnagle, J.H., "Chronic Hepatitis B," <i>The New England Journal of Medicine</i> 323:337-339, Massachusetts Medical Society, Boston, USA (1990)	
	NPL218	Hu, S., et al., "Neutralizing Antibodies Against HIV-1 BRU and SF2 Isolates Generated in Mice Immunized with Recombinant Vaccinia Virus Expressing HIV-1 (BRU) Envelope Glycoproteins and Boosted with Homologous gp160," <i>Aids Research and Human Retroviruses</i> 7:615-620, Mary Ann Liebert, Inc., New York, USA (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (M.D.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/551,209
		Filing Date	September 28, 2005
		First Named Inventor	Denise Marie BAKER
		Art Unit	1644
		Examiner Name	M. DiBrino
		Attorney Docket Number	2473.0260001/EKS/PAC
Sheet	7	of	15

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL219	Jamieson, B.D., <i>et al.</i> , "Effective Clearance of a Persistent Viral Infection Requires Cooperation Between Virus-Specific Lyt2+ T Cells and Non-specific Bone Marrow-Derived Cells," <i>Journal of Virology</i> 61:3930-3937, American Society for Microbiology, Washington DC, USA (1987)	
	NPL220	Kast, W.M., <i>et al.</i> , "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," <i>The Journal of Immunology</i> 152:3904-3912, The American Association of Immunologists, Maryland, USA (1994)	
	NPL221	Kawashima, I., <i>et al.</i> , "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors," <i>Human Immunology</i> 59:1-14, Elsevier Science Inc., New York, USA (1998)	
	NPL222	Khilko, S.N., <i>et al.</i> , "Direct Detection of Major Histocompatibility Complex Class I Binding to Antigenic Peptides Using Surface Plasmon Resonance," <i>The Journal of Biological Chemistry</i> 268:15425-15434, The American Society for Biochemistry and Molecular Biology, Baltimore, USA (1993)	
	NPL223	Kieny, M.D., <i>et al.</i> , "Aids Virus Env Protein Expressed from a Recombinant Vaccinia Virus," <i>Biotechnology</i> 4:790-795, Nature Publishing Company, New York, USA (1986)	
	NPL224	Koenig, S., <i>et al.</i> , "Transfer of HIV-1-specific Cytotoxic T Lymphocytes to an AIDS Patient Leads to Selection for Mutant HIV Variants and Subsequent Disease Progression," <i>Nature Medicine</i> 1:330-336, Nature Publishing Company, New York, USA (1995)	
	NPL225	Kofler, N., <i>et al.</i> , "Preparation and Characterization of Poly-(D,L-Lactide-Co-Glycolide) and Poly-(L-Lactic Acid) Microsphere with Entrapped Pneumotropic Bacterial Antigen," <i>Journal of Immunological Methods</i> 192:25-35, Elsevier Science B.V., Amsterdam, Netherlands (1996)	
	NPL226	Kondo, A., <i>et al.</i> , "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules," <i>The Journal of Immunology</i> 155:4307-4312, The American Association of Immunologists, Maryland, USA (1995)	
	NPL227	Kondo, A., <i>et al.</i> , "Two Distinct HLA-A*0101-Specific Submotifs Illustrate Alternative Peptide Binding Modes," <i>Immunogenetics</i> 45:249-258, Springer-Verlag, Berlin, Germany (1997)	
	NPL228	Kubo, R.T., <i>et al.</i> , "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles," <i>The Journal of Immunology</i> 154:3913-3924, The American Association of Immunologists, Maryland, USA (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	8	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL229	Kuo, G., et al., "An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis," <i>Science</i> 244:362-364, American Association for the Advancement of Science, Washington DC, USA (1989)	
	NPL230	Kyte, J. and Doolittle, R.F., "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>Journal of Molecular Biology</i> 157:105-132, Academic Press Inc., London (1982)	
	NPL231	Lalvani, A., et al., "Rapid Effector Function in CD8 <sup>+</sup> Memory T Cells," <i>Journal of Experimental Medicine</i> 186:859-865, The Rockefeller University Press, New York, USA: (1997)	
	NPL232	Lane, H.C., et al., "Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency Syndrome," <i>The New England Journal of Medicine</i> 313:79-84, The Massachusetts Medical Society, Massachusetts USA (1985)	
	NPL233	Livingston, B.D., et al., "Optimization of Epitope Processing Enhances Immunogenicity of Multiepitope DNA Vaccines," <i>Vaccine</i> 19:4652-4660, Elsevier Science Ltd., New York, USA (2001)	
	NPL234	Ljunggren, H., et al., "Empty MHC Class I Molecules Come Out in the Cold," <i>Nature</i> 346:476-480, Macmillan Magazines Ltd., London (1990)	
	NPL235	Lukacher, A.E., et al., "In Vivo Effector Function of Influenza Virus-Specific Cytotoxic T Lymphocyte Clones is Highly Specific," <i>The Journal of Experimental Medicine</i> 160:814-826, The Rockefeller University Press, New York, USA (1984)	
	NPL236	Lukashov, V.V. and Goudsmit, J., "HIV Heterogeneity and Disease Progression in AIDS: A Model of Continuous Virus Adaption," <i>Aids</i> 12:S43-S52, Lippincott-Raven Publishers, London (1998)	
	NPL237	Malik, A., et al., "Human Cytotoxic T Lymphocytes Against the <i>Plasmodium Falciparum</i> Circumsporozoite Protein," <i>Proc. Natl. Acad. Sci. USA</i> 88:3300-3304, National Academy of Sciences (1991)	
	NPL238	Malone, R.W., et al., "Cationic Liposome-Mediated RNA Transfection," <i>Proc. Natl. Acad. Sci. USA</i> 86:6077-6081, National Academy of Sciences (1989)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	9	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL239	Mannino, R.I. and Gould-Fogerite, S., "Liposome Mediated Gene Transfer," <i>BioTechniques</i> 6:682-690, Eaton Publishing Company, Massachusetts, USA (1988)	
	NPL240	Marshall, K.W., et al., "Role of the Polymorphic Residues in HLA-DR Molecules in Allele-Specific Binding of Peptide Ligands," <i>The Journal of Immunology</i> 152:4946-4957, The American Association of Immunologists, Maryland, USA (1994)	
	NPL241	Matteucci, M.D. and Caruthers, M.H., "Synthesis of Deoxyoligonucleotides on a Polymer Support," <i>Journal of the American Chemical Society</i> 103:3185-3191, American Chemical Society, Washington DC, USA (1981)	
	NPL242	McMichael, A.J., et al., "Cytotoxic T-cell Immunity to Influenza," <i>The New England Journal of Medicine</i> 309:13-17, Massachusetts Medical Society, Boston, Massachusetts, USA (1983)	
	NPL243	McCutchan, T.F. and Waters, A.P., "Mutations with Multiple Independent Origins in Surface Antigens Mark the Targets of Biological Selective Pressure," <i>Immunology Letters</i> 25:23-26, Elsevier Science Publishers BV, Amsterdam, Netherlands (1990)	
	NPL244	Meister, G.E., et al., "Two Novel T cell Epitope Prediction Algorithms Based on MHC-binding Motifs; Comparison of Predicted and Published Epitopes from <i>Mycobacterium Tuberculosis</i> and HIV Protein Sequences," <i>Vaccine</i> 13:581-591, Elsevier Science Ltd., Oxford, UK (1995)	
	NPL245	Milik, M., et al., "Application of an Artificial Neural Network Binding to Predict Specific Class I MHC Binding Peptide Sequences," <i>Nature Biotechnology</i> 16:753-756, Nature America Inc., New York, USA (1998)	
	NPL246	Miller, L.H., et al., "Research Toward Malaria Vaccines," <i>Science</i> 234:1349-1356, American Association for the Advancement of Science, Washington DC, USA (1986)	
	NPL247	Moreno, A., et al., "Cytotoxic CD4 <sup>+</sup> T cells from a Sporozoite-Immunized Volunteer Recognize the <i>Plasmodium Falciparum</i> CS Protein," <i>International Immunology</i> 3:997-1003, Oxford University Press, Oxford, UK (1991)	
	NPL248	Nayersina, R., et al., "HLA A2 Restricted Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes During Hepatitis B Virus Infection," <i>The Journal of Immunology</i> 150:4659-4671, The American Association of Immunologists, Maryland, USA (1993)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.56. The information is required to submit or receive a patent by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	10	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL249	Ogg, G.S., et al., "Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA," <i>Science</i> 279:2103-2106, American Association for the Advancement of Science, Washington DC, USA (1998)	
	NPL250	Oldstone, M.B.A., et al., "Cytoimmunotherapy for Persistent Virus Infection Reveals a Unique Clearance Pattern from the Central Nervous System," <i>Nature</i> 321:239-243, Macmillan Journals Limited, London (1986)	
	NPL251	Ostro, M.J., et al., "Incorporation of High Molecular Weight RNA into Large Artificial Lipid Vesicles," <i>Biochemical and Biophysical Research Communications</i> 76:836-842, Academic Press Inc., New York, USA (1977)	
	NPL252	Panina-Bordignon, P., et al., "Universally Immunogenic T Cell Epitopes: Promiscuous Binding to Human MHC Class II and Promiscuous Recognition by T Cells," <i>European Journal of Immunology</i> 19:2237-2242, Wiley-VCH Verlag GmbH & Co., Weinheim (1989)	
	NPL253	Pantaleo, G., et al., "Major Expansion of CD8 <sup>+</sup> T cells with a Predominant V $\beta$ usage During the Primary Immune Response to HIV," <i>Nature</i> 370:463-467, Macmillan Magazines Ltd., London (1994)	
	NPL254	Papahadjopoulos, D., et al., "Cochleate Lipid Cylinders: Formation by Fusion of Unilamellar Lipid Vesicles," <i>Biochimica et Biophysica Acta</i> 394:483-491, Elsevier Scientific Publishing Company, Amsterdam, Netherlands (1975)	
	NPL255	Parker, K.C., et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>The Journal of Immunology</i> 152:163-175, The American Association of Immunologists, Maryland, USA (1994)	
	NPL256	Penna, A., et al., "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," <i>Journal of Experimental Medicine</i> 174:1565-1570, The Rockefeller University Press, New York, USA (1991)	
	NPL257	Pialoux, G., et al., "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) Followed by a Recombinant Glycoprotein 160 (MN/LAI)," <i>Aids Research and Human Retroviruses</i> 11:373-381, Mary Ann Liebert Inc., New York, USA (1995)	
	NPL258	Pontén, J. and Guo, Z., "Precancer of the Human Cervix," <i>Cancer Surveys</i> 32:201-229, Cold Spring Harbor Laboratory Press, New York, USA (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (M.D.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	11	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL259	Price, D.A., et al., "Positive Selection of HIV-1 Cytotoxic T Lymphocyte Escape Variants During Primary Infection," <i>Proc. Natl. Acad. Sci. USA</i> 94:1890-1895, National Academy of Sciences (1997)	
	NPL260	Quinnan, G.V., et al., "Cytotoxic T Cells in Cytomegalovirus Infection: HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients," <i>The New England Journal of Medicine</i> 307:6-13, Massachusetts Medical Society, Boston, Massachusetts, USA (1982)	
	NPL261	Reay, P.A., et al., "pH Dependence and Exchange of High and Low Responder Peptides Binding to a Class II MHC Molecule," <i>The Embo Journal</i> 11:2829-2839, Oxford University Press, Oxford, UK (1992)	
	NPL262	Reddehase, M.J., et al., "Interstitial Murine Cytomegalovirus Pneumonia After Irradiation: Characterization of Cells That Limit Viral Replication During Established Infection of the Lungs," <i>Journal of Virology</i> 55:264-273, American Society for Microbiology, Washington DC, USA (1985)	
	NPL263	Reichard, O., et al., "Randomised, Double-Blind, Placebo-Controlled Trial of Interferon $\alpha$ -2b with and without Ribavirin for Chronic Hepatitis C," <i>The Lancet</i> 351:83-87, The Lancet Ltd., New York, USA (1998)	
	NPL264	Rénia, L., et al., "In Vitro Activity of CD4 <sup>+</sup> and CD8 <sup>+</sup> T Lymphocytes from Mice Immunized with a Synthetic Malaria Peptide," <i>Immunology</i> 88:7963-7967, Proceedings of the National Academy of Science of the United States of America, Washington DC, USA (1991)	
	NPL265	Ressing, M.E., et al., "Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients with Cervical Carcinoma," <i>Journal of Immunotherapy</i> 23:255-266, Lippincott Williams & Williams Inc., Maryland, USA (2000)	
	NPL266	Romero, P., et al., "Cloned Cytotoxic T Cells Recognize an Epitope in the Circumsporozoite Protein and Protect Against Malaria," <i>Nature</i> 341:323-326, Macmillan Magazines Ltd., London (1989)	
	NPL267	Rosenberg, E.S., et al., "Vigorous HIV-1-Specific CD4 <sup>+</sup> T Cell Responses Associated with Control of Viremia," <i>Science</i> 278:1447-1450, American Association for the Advancement of Sciences, Washington DC, USA (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	12	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL268	Rowen, D. and Lacey, C., "Toward a Human Papillomavirus Vaccine," <i>Dermatologic Clinics</i> 16:835-838, W.B. Saunders Company, Philadelphia, Pennsylvania, USA (1998)	
	NPL269	Schaefer-Ridder, M., et al., "Liposomes as Gene Carriers: Efficient Transformation of Mouse L Cells by Thymidine Kinase Gene," <i>Science</i> 215:166-168, American Association for the Advancement of Sciences, Washington DC, USA (1982)	
	NPL270	Schmitz, J.E., et al., "Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 <sup>+</sup> Lymphocytes," <i>Science</i> 283:857-860, American Association for the Advancement of Sciences, Washington DC, USA (1999)	
	NPL271	Sercarz, E.E., et al., "Dominance and Crypticity of T Cell Antigenic Determinants," <i>Annual Reviews of Immunology</i> 11:729-766, Annual Reviews Inc., Palo Alto, California, USA (1993)	
	NPL272	Sethi, K.K., et al., "Protection of Mice from fatal Herpes Simplex Virus Type 1 Infection by Adoptive Transfer of Cloned Virus-Specific and H-2-Restricted Cytotoxic T Lymphocytes," <i>The Journal of General Virology</i> 64:443-447, Society of General Microbiology, UK (1983)	
	NPL273	Sette, A., et al., "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," <i>Molecular Immunology</i> 31:813-822, Elsevier Science Ltd., Oxford, UK (1994)	
	NPL274	Sidney, J., et al., "Practical Biochemical and Evolutionary Implications of the Discovery of HLA Class I Supermotifs," <i>Immunology Today</i> 17:261-266, Elsevier Science Ltd., Oxford, UK (1996)	
	NPL275	Sidney, J., et al., "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules," <i>Human Immunology</i> 45:79-93, Elsevier Science Inc., New York, USA (1996)	
	NPL276	Sidney, J., et al., "Measurement of MHC/Peptide Interactions by Gel Filtration," in <i>Current Protocols in Immunology</i> , pp. 18.3.1-18.3.19, John Wiley & Sons, Inc. (1998)	
	NPL277	Southwood, S., et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," <i>The Journal of Immunology</i> 160:3363-3373, The American Association of Immunologists, Maryland, USA (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (M.D.)

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	13	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	NPL278	Stover, C.K., et al., "New Use of BCG for Recombinant Vaccines," <i>Nature</i> 351:456-460, Macmillan Magazines Ltd., London (1991)		
	NPL279	Sturniolo, T., et al., "Generation of Tissue-Specific and Promiscuous HLA Ligand Databases Using DNA Microarrays and Virtual HLA Class II Matrices," <i>Nature Biotechnology</i> 17:555-561, Nature America Inc., New York, USA (1999)		
	NPL280	Straubinger, R.M. and Papahadjopoulos, D., "Liposomes as Carriers for Intracellular Delivery of Nucleic Acids," <i>Methods in Enzymology</i> 101:512-539, Academic Press Inc., New York, USA (1983)		
	NPL281	Pfister, K., et al., "Synclalytic conformational changes in aspartate aminotransferase determined by hydrogen-deuterium exchange," <i>Proc. Natl. Acad. Sci. USA</i> 75:145-148, National Academy of Sciences (1978)		
	NPL282	Takahashi, H., et al., "Induction of CD8 <sup>+</sup> Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," <i>Nature</i> 344:873-875, Macmillan Magazines Ltd., London (1990)		
	NPL283	Tam, J.P., "Recent Advances in Multiple Antigen Peptides," <i>Journal of Immunological Methods</i> 196:17-32, Elsevier Science B.V., Amsterdam, Netherlands (1996)		
	NPL284	Thomson, S.A., et al., "Recombinant Polypeptide Vaccines for the Discovery of Multiple CD8 Cytotoxic T Cell Epitopes," <i>The Journal of Immunology</i> 157:822-826, The American Association of Immunologists, Maryland, USA (1996)		
	NPL285	Tigges, M.A., et al., "Human CD8 <sup>+</sup> Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens," <i>Journal of Virology</i> 66:1622-1634, American Society for Microbiology, Washington DC, USA (1992)		
	NPL286	Top, F.H., et al., "Immunization with Live Types 7 and 4 Adenovirus Vaccines. I. Safety, Infectivity, Antigenicity, and Potency of Adenovirus Type 7 Vaccine in Humans," <i>The Journal of Infectious Diseases</i> 124:148-154, The University of Chicago Press, Chicago, USA (1971)		
	NPL287	Townsend, A., et al., "Assembly of MHC Class I Molecules Analyzed In Vitro," <i>Cell</i> 62:285-295, Cell Press, Cambridge, Massachusetts, USA (1990)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/551,209
				Filing Date	September 28, 2005
				First Named Inventor	Denise Marie BAKER
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	14	of	15	Attorney Docket Number	2473.0260001/EKS/PAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T <sup>2</sup>
	NPL288	Tsubota, H., <i>et al.</i> , "A Cytotoxic T Lymphocyte Inhibits Acquired Immunodeficiency Syndrome Virus Replication in Peripheral Blood Lymphocytes," <i>Journal of Experimental Medicine</i> 169:1421-1434, The Rockefeller University Press, New York, USA (1989)		
	NPL289	Vitiello, A., <i>et al.</i> , "Analysis of the HLA-Restricted Influenza-Specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," <i>Journal of Experimental Medicine</i> 173:1007-1015, The Rockefeller University Press, New York, USA (1991)		
	NPL290	Vitiello, A., <i>et al.</i> , "Development of a Lipopeptide-Based Therapeutic Vaccine to Treat Chronic HBV Infection," <i>The Journal of Clinical Investigation</i> 95:341-349, The Rockefeller University Press, New York, USA (1995)		
	NPL291	Verhoef, J.C., <i>et al.</i> , "Des-enkephalin- $\gamma$ -endorphin (DE $\gamma$ E): Biotransformation in Rat, Dog and Human Plasma," <i>European Journal of Drug Metabolism and Pharmacokinetics</i> 11:291-302, Medicine ET Hygiene, Geneva, Switzerland (1986) <b>ABSTRACT ONLY</b>		
	NPL292	Walker, B.D., <i>et al.</i> , "Long-term Culture and Fine Specificity of Human Cytotoxic T-Lymphocyte Clones Reactive with Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 86:9514-9518, National Academy of Sciences (1989)		
	NPL293	Watari, E., <i>et al.</i> , "A Synthetic Peptide Induces Long-Term Protection from Lethal Infection with Herpes Simplex Virus 2," <i>Journal of Experimental Medicine</i> 165:459-470, The Rockefeller University Press, New York, USA (1987)		
	NPL294	Whitton, J.L., <i>et al.</i> , "A 'String-of-Beads' Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge," <i>Journal of Virology</i> 67:348-352, American Society for Microbiology, Washington DC, USA (1993)		
	NPL295	Wilson, T., <i>et al.</i> , "The Introduction of Poliovirus RNA into Cells via Lipid Vesicles (Liposomes)," <i>Cell</i> 17:77-84, The MIT Press, Cambridge, Massachusetts, USA (1979)		
	NPL296	Wolff, J.A., <i>et al.</i> , "Direct Gene Transfer into Mouse Muscle In Vivo," <i>Science</i> 247:1465-1468, American Association for the Advancement of Science, Washington DC, USA (1990)		
	NPL297	Yap, K.L. and Ada, G.L., "Transfer of Specific Cytotoxic T Lymphocytes Protects Mice Inoculated with Influenza Virus," <i>Nature</i> 273:238-239, Macmillan Journals Ltd., London (1978)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Complete if Known*

(Use as many sheets as necessary)

Attorney Docket Number	2473.0260001/EKS/PAC
------------------------	----------------------

72

1071913v1

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 C.F.R. 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO; Time will vary depending upon the individual case. Any fee (and/or the amount of the fee) is to be paid to the USPTO. For more information regarding this burden, please contact the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./